SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics completed a Federal Dispute Resolution (FDR)…

Outlook Therapeutics, Inc. · 8-K filed Apr 21, 2026 at 16:15 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Apr 21, 2026 at 16:15 ET

Outlook Therapeutics completed a Federal Dispute Resolution (FDR) meeting with the FDA to appeal a Complete Response Letter (CRL) for its ONS-5010/ LYTENAVA™ biologics license application. A formal decision from the FDA is expected in May 2026.

  • Company held an FDR meeting with the FDA on April 21, 2026, to appeal a CRL issued on December 30, 2025, for ONS-5010/ LYTENAVA™.
  • The drug is under development for wet AMD and has already received marketing authorization in the EU and UK.
  • The company expects a formal decision from the FDA in May 2026.
  • No financial figures or material changes to operations were disclosed.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access